The company is developing treatment for full or partial reversal of paralysis and improving the lives of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified small interfering RNA (siRNA) sequences. NurExone’s technology is being used to develop treatment of various conditions, including spinal cord injury (SCI), traumatic brain injury, and other CNS indications. An animal study demonstrated that the breakthrough exosome-based technology has immense potential to treat SCI. Following this study, NurExone was granted an exclusive worldwide license from the Technion – Israel Institute of Technology and Tel Aviv University, both located in Israel, to develop and commercialize this technology.